The utility of tau-binding ligands has been studied longitudinally in Alzheimer’s disease research (Jack Jr et al., 2018), but they are yet to be tested in Parkinson’s disease, and may be similarly afflicted by low specificity. This evidence concerns the gene MAPT and Parkinson disease.